Bengaluru: Researchers from Indian Institute of Science (IISc) identified an antibiotic combination that can reverse resistance to isoniazid, a frontline drug for tuberculosis (TB), in laboratory tests and in mice. TB remains one of the world’s most persistent health challenges.The study, “Vancomycin rescues sensitivity to isoniazid in clinical isolates of drug-resistant Mycobacterium tuberculosis,” has been published in Microbiology Spectrum.The team from IISc’s department of biochemistry paired isoniazid with vancomycin. The combination sharply reduced bacterial growth in clinical isolates from drug-resistant TB patients and lowered bacterial load in mice infected with multidrug-resistant (MDR) M. tuberculosis, according to IISc.Isoniazid is a prodrug, which means a bacterial enzyme must activate it before it can work. Mutations in certain genes can block this activation, letting the bacteria survive. Growing resistance has become a major challenge in TB treatment.Vancomycin, used against several bacterial infections, normally struggles to cross the highly impermeable cell wall of M. tuberculosis. The researchers report that when the two drugs are given together, the cell wall loses integrity, allowing vancomycin to enter and kill the bacteria.The team tested isolates from sputum samples of patients with drug-resistant TB, working with National Tuberculosis Institute, Bengaluru. They showed a broad range of isoniazid resistance, allowing the team to test the combination against different resistance mechanisms.The combination substantially outperformed either drug alone. Most isolates showed a more than 90% reduction in bacterial growth, including isoniazid-resistant and MDR strains.The team then tested the combination in mice infected with MDR M. tuberculosis, in collaboration with Amit Singh, professor at IISc’s Centre for Infectious Disease Research and department of microbiology and cell biology.After 10 days of treatment, neither drug alone significantly reduced bacterial burden. Together, they cut bacterial load about 10-fold in both lungs and spleen. Lung tissue also showed fewer granulomas, inflammatory structures that form as the body tries to contain TB infection.“Isoniazid resistance poses a major challenge in TB treatment. To tackle this problem, we started exploring ways to rescue the drug by reversing resistance,” said Nagasuma Chandra, professor at the department of biochemistry and corresponding author of the study.“Although several antibiotic combinations are available for TB treatment, we continue to face challenges due to drug resistance. Our study identifies a drug treatment strategy that can reverse resistance to isoniazid, an otherwise highly effective antibiotic,” said Sukriti Pal, PhD student and the study’s first author.The study’s authors include Pal, Shalini Birua, Singh and Chandra, among others. The combination is not yet ready for use in patients. The team is working to advance it towards clinical trials.“Before the combination can be considered for use in patients, its safety and efficacy need to be studied much more extensively. Clinical trials need to be conducted on drug-resistant TB cases,” Pal said.
